BR112019010485A2 - método para a produção de um anticorpo, anticorpo e formulação farmacêutica - Google Patents

método para a produção de um anticorpo, anticorpo e formulação farmacêutica

Info

Publication number
BR112019010485A2
BR112019010485A2 BR112019010485A BR112019010485A BR112019010485A2 BR 112019010485 A2 BR112019010485 A2 BR 112019010485A2 BR 112019010485 A BR112019010485 A BR 112019010485A BR 112019010485 A BR112019010485 A BR 112019010485A BR 112019010485 A2 BR112019010485 A2 BR 112019010485A2
Authority
BR
Brazil
Prior art keywords
antibody
producing
pharmaceutical formulation
affinity ligand
chain affinity
Prior art date
Application number
BR112019010485A
Other languages
English (en)
Inventor
Walch Heiko
Grunert Ingrid
Thomann Marco
Freiherr Von Roman Matthias
Hingar Michael
Falkenstein Roberto
Dorn Roland
Malik Sebastian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60997429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019010485(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112019010485A2 publication Critical patent/BR112019010485A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção se refere a um método para a produção de um anticorpo que compreende as etapas para formar um complexo de ligante de afinidade de cadeia leve anticorpo-anticorpo, em que o ligante de afinidade de cadeia leve de anticorpo é imobilizado em uma fase sólida, através da aplicação de uma solução que compreende o anticorpo para o ligante de afinidade de cadeia de anticorpo imobilizado, e incubação do complexo formado na etapa anterior com uma ou mais enzimas para modificar a glicosilação do anticorpo, por conseguinte, produzindo o anticorpo.
BR112019010485A 2016-12-21 2017-12-19 método para a produção de um anticorpo, anticorpo e formulação farmacêutica BR112019010485A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16205587 2016-12-21
EP17157002 2017-02-20
PCT/EP2017/083429 WO2018114877A1 (en) 2016-12-21 2017-12-19 In vitro glycoengineering of antibodies

Publications (1)

Publication Number Publication Date
BR112019010485A2 true BR112019010485A2 (pt) 2019-09-10

Family

ID=60997429

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019010485A BR112019010485A2 (pt) 2016-12-21 2017-12-19 método para a produção de um anticorpo, anticorpo e formulação farmacêutica

Country Status (12)

Country Link
US (2) US20200165320A1 (pt)
EP (1) EP3559248B1 (pt)
JP (1) JP6850351B2 (pt)
KR (1) KR102317884B1 (pt)
CN (1) CN110088291A (pt)
AU (1) AU2017384276B9 (pt)
BR (1) BR112019010485A2 (pt)
CA (1) CA3044920C (pt)
IL (1) IL267351A (pt)
MX (1) MX2019006266A (pt)
TW (1) TWI780097B (pt)
WO (1) WO2018114877A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017381657B2 (en) * 2016-12-21 2020-07-23 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
CA3044920C (en) 2016-12-21 2022-06-28 Roberto Falkenstein In vitro glycoengineering of antibodies
JP2021526845A (ja) 2018-07-13 2021-10-11 ゲンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
PE20211858A1 (es) 2018-07-13 2021-09-21 Genmab As Variantes de anticuerpos anti-cd38 y sus usos
IL294453A (en) 2020-01-16 2022-09-01 Genmab As Formulations of cd38 antibodies and uses thereof
AR127743A1 (es) 2021-09-06 2024-02-28 Genmab Bv Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2106301C (en) 1991-03-18 1999-04-06 Chi-Huey Wong Oligosaccharide enzyme substrates and inhibitors: method and compositions
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1460425A1 (en) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Deglycosylated enzymes for conjugates
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
TW200813086A (en) 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP2010536355A (ja) * 2007-08-31 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー グリコシル化プロファイル分析
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
EP2459590B1 (en) 2009-07-30 2015-04-22 F.Hoffmann-La Roche Ag Enzymatic antibody processing
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2012037407A1 (en) 2010-09-17 2012-03-22 Prozyme, Inc. Isolation and deglycosylation of glycoproteins
JP6435193B2 (ja) * 2011-10-19 2018-12-05 ノビミューン エスアー 抗体を精製する方法
IN2014DN06806A (pt) * 2012-02-10 2015-05-22 Univ Maryland
WO2015123754A1 (en) * 2014-02-18 2015-08-27 The University Of Manitoba Methods to produce single glycoform antibodies
EP3191527B1 (en) 2014-09-10 2020-01-15 F.Hoffmann-La Roche Ag Galactoengineered immunoglobulin 1 antibodies
CA3044920C (en) 2016-12-21 2022-06-28 Roberto Falkenstein In vitro glycoengineering of antibodies

Also Published As

Publication number Publication date
CN110088291A (zh) 2019-08-02
MX2019006266A (es) 2019-08-21
US20200165320A1 (en) 2020-05-28
AU2017384276B9 (en) 2020-11-26
KR102317884B1 (ko) 2021-10-26
CA3044920C (en) 2022-06-28
EP3559248A1 (en) 2019-10-30
EP3559248B1 (en) 2021-11-17
AU2017384276A1 (en) 2019-05-30
KR20190082942A (ko) 2019-07-10
CA3044920A1 (en) 2018-06-28
JP6850351B2 (ja) 2021-03-31
TW201835333A (zh) 2018-10-01
US20240101643A1 (en) 2024-03-28
TWI780097B (zh) 2022-10-11
IL267351A (en) 2019-08-29
WO2018114877A1 (en) 2018-06-28
AU2017384276B2 (en) 2020-07-02
JP2020501577A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
BR112019010485A2 (pt) método para a produção de um anticorpo, anticorpo e formulação farmacêutica
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112015017606A2 (pt) composição, método de produzir a composição, utilização da composição e combustível obtido a partir da composição
BR112016015496A2 (pt) composição e processo para a produção da composição
BR112012023276A2 (pt) dispositivo e método de processamento de imagem, e , dispositivo de armazenamento não transitório legível por computador
BR112019005328A2 (pt) composição farmacêutica líquida
BR112015032445A2 (pt) componente semicondutor orgânico
BR112017018028A2 (pt) método de produção de compostos lignocelulósicos
BR112019009839A2 (pt) método para a produção enzimática de um anticorpo e anticorpo
BR112017023238A2 (pt) artigo e método de formação de um artigo
BR112014005018A8 (pt) composição aquosa de ligante, ligante, método de produção de uma composição aquosa de ligante e método de fabricação de um produto selecionado de um grupo
BR112017010923A2 (pt) misturas de milho que incluem milho com alto teor de óleo e métodos de fabricar um ou mais produtos bioquímicos usando milho com alto teor de óleo ou misturas de milho que incluem milho com alto teor de óleo
BR112017010453A2 (pt) composição adesiva com mudança de cor
BR112017012746A2 (pt) produção camada por camada de artigos moldados
BR112016001730A2 (pt) Processo para a preparação de um componente neurotóxico altamente puro de uma toxina botulínica, componente neurotóxico altamente puro de uma toxina de clostridium botulinum e composição farmacêutica
BR112018002036A2 (pt) método para o controle das pragas de um vegetal de algodão e utilização de um ou mais componentes da árvore de ginkgo
BR112018069741A2 (pt) composição para aplicação tópica, e, método para fabricar uma composição para aplicação tópica.
BR112017008802A2 (pt) precursor de recipiente, processo, recipiente fechado e uso do precursor de recipiente
BR112013020873A2 (pt) endoprótese e método para revestimento de uma endoprótese
BR112018070130A2 (pt) método para a coloração parcial de peças plásticas
BR112018002475A2 (pt) método para o controle das pragas de um vegetal de milho e utilização de um ou mais componentes da árvore de ginkgo
BR112017016578A2 (pt) controle do pré-tratamento de um material de partida de madeira macia
BR112019010294A2 (pt) método para a produção enzimática de um anticorpo, anticorpo e formulação farmacêutica
BR102014004766A8 (pt) conjunto de freio com uma asa de freio
BR112017011314A2 (pt) microcápsula, processo para produzir microcápsulas, dispersão aquosa, e, uso de uma microcápsula.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]